

Course Detail

MMWR Weekly - January 28, 2011

Course Number: SS1747-012811

CE Origination Date: January 28, 2011

CE Expiration Date: March 14, 2011

Presenters/Content Experts

Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men

Kevin Fenton, MD, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

R M Grant, MD, MPH, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Amy Lansky, PhD, MPH, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Jonathan Mermin, MD, MPH, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Dawn Smith, MD, MS, MPH, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Paul J. Weidle, Pharm.D, MPH, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Lead Poisoning of a Child Associated with Use of a Cambodian Amulet

Jacqueline Ehrlich, MD, MPH, Lead Poisoning Prevention Program, New York City Department of Health and Mental Hygiene

Chinaro M. Kennedy, DrPH, MPH, Health Homes & Lead Poisoning Prevention Branch, NECH, CDC

Mana Mann, MD, MPH, Lead Poisoning Prevention Program, New York City Department of Health and Mental Hygiene

Mia Rublowska, RN, Lead Poisoning Prevention Program, New York City Department of Health and Mental Hygiene

Marissa S. Sucusky, MPH, Health Homes & Lead Poisoning Prevention Branch, NECH, CDC

Updated Recommendations for Use of Meningococcal Conjugate Vaccines – Advisory Committee on Immunization practices (ACIP), 2010

Amanda Cohn, MD, Medical Epidemiologist, Meningitis and Vaccine Preventable Disease Branch, NCIRD, CDC

Notes from the Field – Respiratory Diphtheria – Like Illness Caused by Toxigenic *Corynebacterium ulcerans* – Idaho, 2010

Sky R. Blue, MD, Sawtooth Epidemiology and Infectious Diseases

Kris K. Carter, DVM, MPVM, USPHS, Idaho Department of Health and Welfare

Pamela Cassiday, MS, Division of Bacterial Diseases, NCIRD, CDC

James Colburn, PhD, MSPH, EIS Officer, EFAB, OSELS, CDC

Christine Hahn, MD, Idaho Department of Health and Welfare

Tejpratap Tiwari, MD, Division of Bacterial Diseases, NCIRD, CDC,

Disclosure

CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dawn Smith's discussion of antiretroviral agents. She will be discussing guidance on the use of antiretroviral agents for the prevention of HIV infection among MSM. Medications have a labeled indication for the treatment of HIV infection but off-label use is permitted. Guidance is based on the results of a large clinical trial showing substantial efficacy for prevention. The pharmaceutical company is in discussions with FDA to apply for a prevention labeling indication. FDA has cleared the content of this interim guidance for off-label use. Dr. Paul Weidle has a discussion on pre-exposure prophylaxis. He will discuss the use of pre-exposure prophylaxis is not a FDA labeled indication for tenofovir/emtricitabine (Truvanda). Dr. Tejpratap Tiwari has a discussion on diphtheria antitoxin. He will be discussing FDA- licensed diphtheria antitoxin (DAT) product being unavailable for use in the USA since 1997. However, DAT is currently available for use under a FDA-approved Investigational New Drug Protocol which is managed by CDC. Physicians/health care providers can obtain DAT from CDC upon request for treatment of suspected diphtheria cases.

No commercial support.

Mechanism(s) to Resolve Real and Perceived Conflicts of Interest: Planner(s) reviewed content and it was cleared before publication.